Capivasertib Plus Faslodex Meets Both Primary Endpoints in Phase 3 Trial for Breast Cancer
October 28th 2022Results demonstrate improved progression-free survival in the overall patient population and in a prespecified biomarker subgroup of tumors with alterations in specific genes, AstraZeneca says.
Read More
Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 4 with Crystal Yu
October 27th 2022Strengthening partnerships with healthcare professionals and driving awareness on the clinical benefits of dermatological skincare is the key to success in the public health space.
Listen